^
    15h
    Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Jennifer Woyach | Initiation date: May 2026 --> Sep 2026
    Trial initiation date
    |
    clonoSEQ®
    |
    Venclexta (venetoclax) • nemtabrutinib (MK-1026)
    15h
    A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant (clinicaltrials.gov)
    P1, N=46, Recruiting, City of Hope Medical Center | Trial completion date: Feb 2030 --> May 2028 | Trial primary completion date: Feb 2030 --> May 2028
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Triplex (CMV-MVA vaccine)
    19h
    RG1716009: Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, University of Washington | Trial completion date: Jan 2031 --> Jan 2028
    Trial completion date
    |
    Rituxan (rituximab) • Ninlaro (ixazomib) • Truxima (rituximab-abbs)
    23h
    BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Luminary Therapeutics
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    1d
    Economic Analysis of Alliance A041202 CLL Study (clinicaltrials.gov)
    P=N/A, N=55, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2026 --> Dec 2026
    Trial completion date • HEOR
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine
    1d
    Atalanta-1: A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=130, Terminated, Lakefront Biotherapeutics NV | Trial completion date: Jul 2029 --> May 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2029 --> May 2026; Following the decision by Galapagos NV to wind down its cell therapy programs, the study was early terminated at the end of the study treatment period for the last subject (27-May-2026).
    Trial completion date • Trial termination • Trial primary completion date
    2d
    Focal adhesion kinase FAK interplays with ROR1 in the aggressiveness of chronic lymphocytic leukemia. (PubMed, BMC Med)
    Our findings reveal a reciprocal regulatory relationship between FAK and ROR1, with both proteins enriched in CLL cells that have exited the lymph nodes. Given defactinib's favorable safety profile in solid tumor trials, combining FAK inhibition with BTK inhibitors could enhance therapeutic efficacy by limiting leukemic clone adaptability and addressing resistance and relapse. While anti-ROR1 therapies showed limited efficacy as monotherapy in CLL trials, targeting multiple nodes of this regulatory network may prove more effective.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • CD5 (CD5 Molecule) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • ANXA5 (Annexin A5) • CTTN (Cortactin)
    |
    Imbruvica (ibrutinib) • Fakzynja (defactinib)
    2d
    Real-world clinical outcomes in patients with CLL previously treated with covalent BTKi and BCL2i regimens. (PubMed, Blood Neoplasia)
    Our results suggest an unmet need among patients with DR CLL. Future studies should continue to evaluate response durability with different treatments in DE and DR CLL populations.
    Clinical data • Journal • Real-world evidence
    |
    BCL2 (B-cell CLL/lymphoma 2)
    2d
    A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Nave Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    clonoSEQ®
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax)
    3d
    CaDAnCe-303: A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors (clinicaltrials.gov)
    P3, N=153, Active, not recruiting, BeOne Medicines | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rituxan (rituximab) • bendamustine • catadegbrutinib (BGB-16673)
    3d
    Study of the Metabolism in the Lymphatic Niche of CLL (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Centre Hospitalier Universitaire de Nice | Trial completion date: Dec 2022 --> Jun 2027
    Trial completion date
    3d
    A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies (clinicaltrials.gov)
    P1, N=35, Completed, AstraZeneca | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Sep 2025
    Trial completion • Trial completion date
    |
    Gazyva (obinutuzumab) • Calquence (acalabrutinib)